

Dermatitis

Andrei Metelitsa, MD, FRCPC, FAAD
Clinical Associate Professor, Dermatology, U of C
Co-Director, Institute for Skin Advancement

Copyright © 2017 by Sea Courses Inc.

All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means – graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law.

Sea Courses is not responsible for any speaker or participant's statements, materials, acts or omissions.

Learning Objectives

- Discuss variants of dermatitis
- Understand basic principles of treatment
 - Moisturization
 - Topical corticosteroids

Xerosis (dry skin)

- Very common
- Many causes:
 - Dry environment (winter)
 - Age (common in elderly)
 - Overuse of soap
 - Prolonged, excessive exposure to water
 - Medical conditions (renal failure, HIV, etc.)
 - Medications (e.g. isotretinoin)
 - Most often combination of above and other factors



Xerosis in renal failure



**Xerosis leading to
eczema**

(asteatotic eczema)

Eczema/Dermatitis

- Eczema = “to boil over”
- Dermatitis and eczema used interchangeably in practice
- Common way for skin to react
- Acute vs. chronic

Dermatitis classification

Acute

- Erythema
- Edema
- Papules
- Vesicles
- Crust

Chronic

- Lichenification
- Scaling
- Hyperpigmentation
- Fissures



Dermatitis

- Atopic Dermatitis
- Stasis Dermatitis
- Nummular Dermatitis
- Contact Dermatitis
 - Allergic vs. Irritant
- Seborrheic Dermatitis
- Rare forms

1. Atopic Dermatitis

- inherited, chronic, relapsing and pruritic skin condition
- 3 different forms:
 - infantile
 - childhood
 - adulthood
- often associated with xerosis and atopy

Atopy

- genetic predisposition to mucosal and cutaneous hyperreactivity
- “atopic triad” refers to atopic dermatitis, allergic rhinitis (hay fever) and asthma (up to 80% association)
- usually:
 - atopic dermatitis appears first
 - then asthma
 - then allergic rhinitis

DIAGNOSTIC FEATURES OF ATOPIC DERMATITIS

Major features (3 of 4 present)

- Pruritus
- Typical morphology and distribution of skin lesions (Figs 13.3 & 13.14)
- Chronic or chronically relapsing dermatitis
- Personal or family history of atopy

Minor features (3 of 23 present)

- Xerosis
- Ichthyosis/palmar hyperlinearity/keratosis pilaris (Figs 13.8 & 13.10)
- Immediate (type I) skin test reactivity
- Elevated serum IgE
- Early age of onset
- Tendency toward cutaneous infections/impaired cell-mediated immunity
- Tendency toward non-specific hand or foot dermatitis
- Nipple eczema
- Cheilitis (Fig. 13.12)
- Recurrent conjunctivitis
- Dennie–Morgan infraorbital fold (Fig. 13.9)
- Keratoconus
- Anterior subcapsular cataract
- Orbital darkening
- Facial pallor/erythema (Figs 13.6 & 13.9)
- Pityriasis alba (Fig. 13.11)
- Anterior neck folds
- Pruritus when sweating
- Intolerance to wool and lipid solvents
- Perifollicular accentuation (Fig. 13.4)
- Food intolerance
- Course influenced by environmental/emotional factors
- White dermographism/delayed blanch

Table 13.1 Diagnostic features of atopic dermatitis.

From Bolognia, Jorizzo & Rapini: Dermatology 2e. © 2008 Elsevier, Ltd.

Atopic Dermatitis

- Many children present before 3 month of age
 - most (85%) within first year of life
 - uncommon (<5%) to develop AD after 5
- of patients affected:
 - 50% clear by grade I and
 - 75% by junior high
 - if AD persists, it usually decreases in severity

Atopic Dermatitis – Infantile



© 2003 Elsevier - Bolognia, Jorizzo and Rapini: Dermatology - www.dermtext.com




CLINIQUE DERMATOLOGIQUE
Par 334-40 06 21 17



CENTRE HOSPITALIER
UNIVERSITAIRE DE NANTES

© Clinique Dermatologique - CHU NANTES

Atopic Dermatitis – Infantile




Atopic Dermatitis – Childhood



© Mayo Foundation for Medical Education and Research. All rights reserved.

Atopic Dermatitis – Adult



From Bologna, Jorizzo & Rapini: Dermatology 2e. © 2008 Elsevier, Ltd.



From Bologna, Jorizzo & Rapini: Dermatology 2e. © 2008 Elsevier, Ltd.




From Bolognia, Jorizzo & Rapini: Dermatology 2e. © 2008 Elsevier, Ltd.

Associated Clinical Features

- Pruritus
- Xerosis
- Keratosis Pilaris
- Ichthyosis Vulgaris
- Post-inflammatory hypopigmentation

Keratosis Pilaris



Ichthyosis Vulgaris



From Bolognia, Jorizzo & Rapini: Dermatology 2e. © 2008 Elsevier, Ltd.

Atopic Dermatitis - Treatment

- i) avoidance of trigger factors:
 - wool and abrasive clothing
 - soaps and detergents,
 - heat, perspiration
 - stress, alcohol
 - foods (if food allergy implicated in a given patient)
 - dust mites (if implicated)

Atopic Dermatitis - Treatment

- ii) Dryness:
 - Moisturization routine:
 - Bathing in pure lukewarm water for 5-20 minutes
 - Follow immediately with :
 - petroleum jelly, thick bland moisturizers;
 - if less severe – lighter moisturizing creams
 - This “traps” water in the skin
 - Advanced Moisturizers:
 - Ceramide-based creams

Atopic Dermatitis - Treatment

- iii) Inflammation – anti-inflammatories:
 - topical steroids:
 - preferably ointments (sting less, better efficacy)
 - too strong and too long may cause thinning of the skin and other side effects
 - too weak or too short – no result, frustration
 - topical immunosuppressives (pimecrolimus – Elidel and tacrolimus – Protopic);
 - not as effective as steroids but safer in the long run
 - systemic steroids and other immunosuppressives may be necessary in occasional patients (e.g. methotrexate, cyclosporine, azathioprine)
 - light therapy (e.g. nUVB) can also be used for its effect on the skin immune system

Atopic Dermatitis - Treatment

- iv) Pruritus – oral antihistamines:
 - hydroxyzine (Atarax) and
 - diphenhydramine (Benadryl)
 - likely working through their sedative effect and breaking the itch-scratch cycle
 - newer antihistamines (e.g. cetirizine, loratadine) are not usually effective for skin except for some individual cases

Atopic Dermatitis - Treatment

- v) superinfection – *S. aureus*:
 - skin of patients with atopic dermatitis is especially hospitable to *S. aureus*
 - *S. aureus*, in turn, worsens eczema through release of superantigents.
 - “vicious cycle”
 - “impetiginization”

Atopic Dermatitis - Treatment

Often need antibacterial treatment

- topical: mupirocin or fucidin
- systemic: cloxacillin, cephalexin, erythromycin
- “decontamination” with bleach baths: about 1/3 cup per 40 liters bath (2 teaspoons per gallon)

Atopic Dermatitis - Treatment

- vi) Keratosis Pilaris or Ichthyosis
 - Consider using keratolytics
(e.g Uremol -10 or Uremol-20)

Typical Regiment for Moderate Dermatitis

- Bathing daily
- Moisturization bid
- Topical corticosteroid (e.g. hydrocortisone 1% cream – face, betamethasone 0.1% valerate cream - body) bid +/- fucidin
 - “3 weeks on / 1+ week off” to avoid skin thinning
 - stop once clear; start at first sign of it coming back
- Atarax qhs
- Consider a course of oral antibiotics

Dupilumab (Dupixent)

- 2017 FDA and subsequent Health Canada
- Human monoclonal antibody inhibitor of IL4
- Inhibits IL4 and IL13 signaling (TH2)
- Adult patients with moderate-to- severe atopic dermatitis whose disease is not adequately controlled with topical therapies

Dupilumab Dosing

- 600 mg sq initial dose followed by 300 mg SQ q2 weeks

Adverse Reactions

Adverse Reaction	DUPIXENT Monotherapy ^a	
	Placebo N=517 n (%)	DUPIXENT 300 mg Q2W N=529 n (%)
Injection site reaction	28 (5.4%)	51 (9.6%)
Conjunctivitis ^c	12(2.3%)	51(9.6%)
Blepharitis	1 (0.2%)	2 (0.4%)
Oral herpes	8 (1.5%)	20 (3.8%)
Eye pruritus	1 (0.2%)	3 (0.6%)
Dry eye	0	1 (0.2%)
Herpes simplex ^c	4 (0.8%)	9 (1.7%)
Keratitis ^e	0	1 (0.2%)
Eosinophilia	2 (0.4%)	9 (1.7%)

2. Stasis Dermatitis

Stasis Dermatitis

- fairly common in elderly
- often bilateral
 - around lower part of calf and shin
 - background of swelling.
- commonly confused with cellulitis
- pruritic, therefore subject to scratching
 - which makes it worse
- ulceration is a common complication

2. Stasis Dermatitis



Stasis Dermatitis



Stasis Dermatitis - Treatment

- relieve the swelling
 - compression stockings, if safe
 - elevation
- moderate or potent topical steroids
 - e.g amcinonide ungt bid
- beware of complications:
 - patients with stasis dermatitis are particularly prone to developing allergic contact dermatitis (e.g. to neomycin, lanolin, herbals, etc.)

Beware of Complications

- Patients are prone to developing allergic contact dermatitis (e.g. to neomycin, lanolin, herbals, etc.)

3. Nummular Dermatitis

- Coin-shaped disseminated eczematous lesions
 - Mainly extremities
- Usually very pruritic
- Chronic course

Treatment

- Medium- to high-potency topical corticosteroids
- Topical calcineurin inhibitors
- +/- phototherapy

4. Allergic Contact Dermatitis

- Pruritic eczematous reaction
- Usually localized to the site of contact with the allergen
 - May have diffuse distribution
- Prototypic reactions are due to poison ivy and nickel
- Patch testing is gold standard
 - Used to detect culprit allergen
- Topical corticosteroids for acute flares

5. Irritant Contact Dermatitis

- Acids
- Alkalies
- Metal Salts
- Solvents
- Alcohols
- Detergents
- Disinfectants
- Plastics

ACD/ICD treatment

- Identify causative allergen or irritant and avoid it
- Barrier creams (e.g Prevex)
- Potent topical corticosteroids
- +/- Systemic corticosteroids
- May take 6 weeks or more to see complete and prolonged clearing!


Alitretinoin (Toctino)

- The first and only treatment approved in Canada to treat severe CHD refractory to high-potency TCS in adults
- 10 and 30 mg oral capsules, taken at least for 3 months
- Safe tolerability profile, positive impact on quality of life
- Teratogenic: pregnancy prevention is essential

Toctino

- Headache: most frequently reported AE
 - more common in the 30 mg group (21.6%) vs the 10 mg group (11.3%) ²⁹
- Flushing, erythema, dry lip also observed, and were dose-dependent ²⁹
- The most common lab changes: ²⁹
 - Increased triglycerides
 - Increased cholesterol
 - Decreased TSH and T4 free thyroxine

Canadian Hand Dermatitis Management Guidelines



Adapted from the 2010 Canadian Hand Dermatitis Management Guidelines ¹

Topical Corticosteroids

- Most inflammatory skin conditions respond to topical corticosteroids
- Various potencies
 - strongest are approx. 1,800 times stronger than OTC hydrocortisone
- Various formulations
 - ointments, oil-based solutions, creams, lotions, gels, alcohol-based solutions, foams, sprays, powders, etc.

Topical Corticosteroids

- Potency depends on: chemical structure of the steroid molecule, concentration, and formulation/vehicle
- Clinical effect depends on frequency and mode of application (e.g. under occlusion), skin characteristics, etc.
- Potency translates into therapeutic effect but also likelihood of side effects
- There is no perfect measure for potency

Potency Chart

POTENCY RANKING OF SOME COMMONLY USED TOPICAL GLUCOCORTICOSTEROIDS

Class 1 (Superpotent)

- Clobetasol propionate gel, ointment, cream and foam 0.05%
- Betamethasone dipropionate gel* and ointment* 0.05%
- Diflorasone diacetate ointment* 0.05%
- Fluocinonide cream 0.1%
- Flurandrenolide tape 4 µg/cm²
- Halobetasol propionate ointment and cream 0.05%

Class 2 (High Potency)

- Amcinonide ointment 0.1%
- Betamethasone dipropionate cream* and ointment 0.05%
- Clobetasol propionate solution ('scalp application') 0.05%
- Desoximetasone ointment and cream 0.25% and gel 0.05%
- Diflorasone diacetate ointment and cream* 0.05%
- Fluocinonide gel, ointment, cream and solution 0.05%
- Halcinonide ointment and cream 0.1%
- Mometasone furoate ointment 0.1%

Class 3 (High Potency)

- Amcinonide cream and lotion 0.1%
- Betamethasone dipropionate cream and lotion 0.05%
- Betamethasone valerate ointment 0.1%
- Desoximetasone cream 0.05%
- Diflorasone diacetate cream 0.05%
- Fluticasone propionate ointment 0.005%
- Triamcinolone acetonide ointment 0.1% and cream 0.5%

Class 4 (Medium Potency)

- Betamethasone valerate foam 0.12%
- Fluocinolone acetonide ointment 0.025%
- Flurandrenolide ointment 0.05%
- Hydrocortisone valerate ointment 0.2%
- Mometasone furoate cream and lotion 0.1%
- Triamcinolone acetonide ointment (Kenalog®) and cream 0.1%

Class 5 (Medium Potency)

- Betamethasone dipropionate lotion 0.05%
- Betamethasone valerate cream and lotion 0.1%
- Clocortolone pivalate cream 0.1%
- Fluocinolone acetonide cream 0.025% and oil 0.01%
- Fluticasone propionate cream and lotion 0.05%
- Flurandrenolide cream and lotion 0.05%
- Hydrocortisone butyrate ointment, cream and lotion 0.1%
- Hydrocortisone probutate cream 0.1%
- Hydrocortisone valerate cream 0.2%
- Prednicarbate ointment and cream 0.1%
- Triamcinolone acetonide lotion 0.1%

Class 6 (Low Potency)

- Aclometasone dipropionate ointment and cream 0.05%
- Triamcinolone acetonide cream 0.1% (Aristocort®)
- Betamethasone valerate lotion 0.1%
- Desonide gel, ointment, cream, lotion and foam 0.05%
- Fluocinolone acetonide cream 0.01% and solution 0.05%
- Triamcinolone acetonide cream and lotion 0.025%

Class 7 (Low Potency)

- Topicals with hydrocortisone, dexamethasone and prednisolone

*Optimized vehicle.

Simplified Potency Chart

- Low potency: hydrocortisone
(e.g. Hydroval)
- Medium potency: betamethasone 0.1% valerate
(e.g. Betaderm cream)
- High potency: amcinonide cream
(e.g. Cyclocort)
- Super potent: clobetasol propionate
(e.g. Dermovate ungt)

Topical Corticosteroids

- choice of topical corticosteroid preparation depends on:
 - the condition under treatment
 - body site
 - body surface area
 - patient age
 - etc.

Topical Corticosteroids

- differences in vehicle/formulation strongly affect potency
 - differences of two or three classes between preparations with the same corticosteroid molecule
 - ointments are generally more potent than creams
- substitution with generics is not straightforward
 - some generics are significantly less potent than brand names
- application under occlusion can increase efficacy by up to 100-fold but also increases side effects
- hydration will aid greatly in penetration and efficacy

Steroid Atrophy



**2-3 weeks on/1 week off
regimen should
decrease risk of
atrophy**

Telangiectasia, erythema, atrophy



Striae



Perioral Dermatitis



Other Side Effects


- Hypopigmentation
- Purpura
- Erythema
- Decreased wound healing
- Steroid dependency
- Worsening of infections and infestations
- Tachyphylaxis – loss of efficacy with continued use
- Burning and itching, etc.

Rare Systemic Side Effects

- Especially potent steroids
 - over large surface areas
 - in kids
 - under occlusion
- mild hypercortisolism,
- HPA axis suppression,
- very rarely Cushing's syndrome

6. Seborrheic Dermatitis

- Infantile and adult forms
- overgrowth of *Malassezia (Pityrosporum)* yeast
- Lesions favour the scalp, ears, face, central chest, and intertriginous areas
- well-demarcated, red, inflamed area covered with greasy, bran-like, often yellowish scale



© 2003 Elsevier - Bolognia, Jorizzo and Rapini: Dermatology - www.dermtext.com

Adult seborrheic dermatitis

Infantile

- Increased sebum production during the first few months of life.
- Most common in infants is “cradle cap”
- Other areas of the body
 - face, skin folds, diaper area, trunk and extremities.
- Conservative treatment with bathing and application of emollients is advised in most cases
 - topical ketoconazole and topical steroids reserved for severe cases

Adult

- Dandruff is most common manifestation
- Often has a chronic or relapsing course.
- More severe cases dermatitis may be seen throughout scalp, around eyebrows, eyelashes, on the forehead, face, an even chest
- Treatment of dandruff can be achieved with
 - zinc pyrithione shampoos (Head&Shoulders)
 - topical corticosteroids
 - topical antifungals (ciclopirox olamine – Stieprox)

PEARLs

- ◆ Dermatitis treatments include
 - ◆ topical corticosteroids (4 main potency groups)
 - ◆ topical calcineurin inhibitors
 - ◆ +/- systemic agents and phototherapy
 - ◆ Novel biologics (dupilumab) – targeted therapy
 - ◆ Chronic hand dermatitis - alitretinoin